Anthera Pharmaceuticals(OTC) ANTH

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company is advancing a pipeline that includes innovative treatments for exocrine pancreatic insufficiency and autoimmune diseases.

Products and Services

• Sollpura: Investigational non-porcine pancreatic enzyme replacement therapy
• Blisibimod: Targeting B-cell mediated autoimmune diseases
• Licensing agreements with Amgen, Inc. and Eli Lilly and Company

Growth Outlook

• Pipeline includes therapies in late-stage clinical trials
• Focus on addressing significant unmet medical needs in healthcare
• Potential for strategic partnerships to enhance development capabilities

Financial Highlights

• Recent quarterly revenue of $0, reflecting ongoing development phase
• Trailing twelve months (TTM) net income shows a loss of $44.34 million
• Cash and cash equivalents of $8.09 million as of March 31, 2018

Anthera Pharmaceuticals operates in the biotechnology sector, emphasizing the development of innovative therapies. The company’s lead product, Sollpura, is currently in Phase III clinical trials, which could position it favorably in the market if successful. Additionally, Blisibimod is being evaluated for its efficacy in treating autoimmune diseases, indicating a diverse pipeline aimed at addressing critical health issues. Despite the challenges reflected in the financial data, including a significant net loss, the company maintains a strategic focus on advancing its clinical programs. The presence of licensing agreements with established pharmaceutical companies like Amgen and Eli Lilly may provide additional resources and validation for Anthera's initiatives. The current cash position allows for continued operations while pursuing potential partnerships and further development of its product candidates.